Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks

Bristol Myers Squibb (BMY) reported a serious adverse event in its phase 1 trial for CAR-T therapy zolacabtagene autoleucel, including a patient death. Early efficacy data showed promise for multiple sclerosis treatment. The company offers a 4.02% dividend yield with a 41% payout ratio and a GF Value of $56.82, suggesting fair valuation. BMY's GF Score is 72, reflecting solid financial health.

Bristol-Myers Squibb (BMY) stock fell 2% after a patient death in an early-stage CAR T trial for multiple sclerosis. Despite this, the trial showed promising efficacy results, with all 60 higher-dose patients remaining off regular MS drugs. BMY stock is up 14% year-to-date, and retail sentiment remains bullish. According to StockTwits.

Bristol Myers Squibb shared interim results from its Phase 1 Breakfree-2 study of zolacabtagene autoleucel (zola-cel) in multiple sclerosis. The study included 66 patients, showing a safety profile consistent with prior data and promising efficacy. 42.4% had cytokine release syndrome, mostly Grade 1. One fatal event occurred due to septic pneumonia. All patients at dose level 2 remained off disease-modifying therapies, with some showing improved disability progression.

Bristol-Myers Squibb's shares declined after a patient death in its Phase 1 Breakfree-2 multiple sclerosis study. The company disclosed the incident, leading to a 2.02% drop in share price. The study is an early-stage cell therapy trial.

Eli Lilly and Company (LLY) has begun construction on a $5 billion manufacturing facility near Richmond, VA, as part of a $50 billion US expansion plan. The site will produce active pharmaceutical ingredients (API) and finished medicines, including antibody-drug conjugates (ADCs) for cancer and autoimmune treatments. The project is expected to create 650 jobs and will use advanced technologies like AI and machine learning.

Bristol Myers Squibb reported a patient death in an early-stage trial of its experimental CAR-T cell therapy, zolacabtagene autoleucel, due to septic pneumonia. The patient received a high-dose chemotherapy and died 44 days after the infusion. The company's shares fell 2.5% in early trading on Friday. In September, Bristol Myers Squibb paused zola-cel studies for safety reviews.